Uncategorized

Own the Clock: How Pharma Companies Extract Maximum Value from Patent Term Extensions and Secondary Patents

Pharma doesn’t just “own” a patent term. It engineers it.
In a world where blockbuster revenues are increasingly shaped by regulatory timing, the real competitive edge often isn’t the original patent—it’s what comes after. A new post from DrugPatentWat…

Own the Clock: How Pharma Companies Extract Maximum Value from Patent Term Extensions and Secondary Patents Read Post »

Uncategorized

The Authorized Generic Playbook: Why Brands Launch Their Own Competition, Even if There is No Competition

Brands Don’t Launch “Competition” by Accident—They Do It to Control the Next Phase of the Market
There’s a quiet strategy playing out across pharma that most investors only notice after the damage is done: the authorized generic.
On the surface, it loo…

The Authorized Generic Playbook: Why Brands Launch Their Own Competition, Even if There is No Competition Read Post »

Uncategorized

Pick the Right FDA Pathway and You Own the Market. Pick the Wrong One and You’re Funding Your Competitor.

Pick the Right FDA Pathway—and You Own the Market. Pick the Wrong One—and You’re Funding Your Competitor.
In pharma, the most expensive mistake isn’t a failed clinical trial. It’s a strategic misstep that happens after the science is done—when you choo…

Pick the Right FDA Pathway and You Own the Market. Pick the Wrong One and You’re Funding Your Competitor. Read Post »

Biotechblog
Scroll to Top